Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

PURPOSE: To determine whether the effect of a single initial intravitreal injection of bevacizumab for neovascular age-related macular degeneration (AMD) persists for 8 weeks. METHODS: We reviewed the records of 25 consecutive patients with neovascular AMD treated with intravitreal bevacizumab. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Conrad, P William, Zacks, David N, Johnson, Mark W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699802/
https://www.ncbi.nlm.nih.gov/pubmed/19668423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699802/
https://www.ncbi.nlm.nih.gov/pubmed/19668423

Ejemplares similares